In this solo episode of Pharma Talks, Nataliya Andreychuk takes an unfiltered look at one of the biggest challenges emerging from AI adoption in the pharmaceutical industry: the velocity trap.
Pharma is investing billions in artificial intelligence, accelerating content production, expanding into new channels, and making localization easier than ever. Yet at the same time, huge volumes of approved content are never used.
Nataliya explores what happens when AI-powered content creation moves faster than the workflows, relationships, and human expertise needed to make that content meaningful. She looks at the gap between content production and HCP engagement, the role of AI-native pharma organizations, and why AI may be exposing — rather than solving — broken pharmaceutical content workflows.
The conversation also introduces the HUMICS framework and explores the uniquely human capabilities that will become even more important in an AI-native pharmaceutical organization.
00:00 Welcome to a solo episode of Pharma Talks
00:07 Pharma’s massive AI investment and the race for efficiency
02:00 The AI content “velocity trap”
04:00 Why more content doesn’t necessarily mean more engagement
06:00 AI-native pharma and the future of human expertise
08:00 The HUMICS framework
10:00 Human-in-the-loop, MLR and compliant AI
12:00 The AI roadmap pharma leaders should be building
📲 Enjoyed this episode?
👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode
👉 Want to be a guest? Plan your recording with Nataliya Andreychuk.
🔗 Follow & Connect:
🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/
